Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 6/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.56 |
| ▸ | SLC5A2 | P31639 | 8/20 | 0.54 |
| ▸ | SLC5A1 | P13866 | 6/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19189971 | 1.00 | CYP2C19 (0.56) | CYP2C19CYP2C9SLC5A2SLC5A1THRB | |
| SCHEMBL10031325 | 0.81 | SLC5A1 (0.63) | CYP2C19CYP2C9SLC5A2SLC5A1THRB | |
| SCHEMBL10031321 | 0.81 | SLC5A1 (0.63) | CYP2C19CYP2C9SLC5A2SLC5A1THRB | |
| SCHEMBL6860722 | 0.79 | TSHR (0.54) | CYP2C19CYP2C9THRBTSHRCYP3A4 | |
| SCHEMBL3350751 | 0.79 | TSHR (0.54) | CYP2C19CYP2C9THRBTSHRCYP3A4 | |
| SCHEMBL23818232 | 0.78 | SLC5A2 (0.60) | CYP2C19SLC5A2SLC5A1CYP3A4 | |
| SCHEMBL17866100 | 0.76 | ALDH1A1 (0.45) | CYP2C19CYP2C9SLC5A2SLC5A1CYP3A4 | |
| SCHEMBL675703 | 0.76 | SLC5A2 (0.50) | CYP2C19CYP2C9SLC5A2SLC5A1THRB | |
| SCHEMBL23619235 | 0.75 | ALDH1A1 (0.43) | CYP2C19CYP2C9SLC5A2SLC5A1CYP3A4 | |
| SCHEMBL15681552 | 0.73 | CYP2C19 (0.43) | CYP2C19CYP2C9SLC5A2SLC5A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776449-B1 | PROCESS FOR THE PREPARATION OF BETA-C-ARYL GLUCOSIDES | SCINOPHARM TAIWAN LTD (TW) | 2017-08-02 | — | — | EP | disclosed |
| US-8952139-B2 | Process for the preparation of β-C-aryl glucosides | SCINOPHARM TAIWAN, LTD (TW) | 2015-02-10 | — | — | US | disclosed |
| US-8952139-B2 | Process for the preparation of β-C-aryl glucosides | SCINOPHARM TAIWAN, LTD (TW) | 2015-02-10 | — | — | US | disclosed |
| US-20140128595-A1 | Process for the Preparation of ß-C-Aryl Glucosides | SCINOPHARM TAIWAN, LTD. (TW) | 2014-05-08 | — | — | US | disclosed |
| US-20140128595-A1 | Process for the Preparation of ß-C-Aryl Glucosides | SCINOPHARM TAIWAN, LTD. (TW) | 2014-05-08 | — | — | US | disclosed |
| WO-2013068850-A2 | PROCESS FOR THE PREPARATION OF β-C-ARYL GLUCOSIDES | SCINOPHARM TAIWAN, LTD. (NA) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128595-A1 | Process for the Preparation of ß-C-Aryl Glucosides | SLC5A2, SLC5A1, UGGT1 | CYP2C19 273/4885CYP2C9 183/4885SLC5A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.